Venrock Adviser, LLC
13F Reported Value
ⓘ$3.3B
Holdings
33
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Venrock Adviser, LLC disclosed 33 positions worth $3.3B in its Form 13F-HR for Q2 2026, led by $APGE (Apogee Therapeutics, Inc.) at 34.2% of the equity portfolio, followed by $ORKA and $ERAS. During the quarter the fund opened 4 new positions and exited 4 — including a new stake in $ACHV and a full exit from $KALV. The portfolio is most concentrated in Healthcare (99.9% of disclosed assets). All figures are sourced directly from Venrock Adviser, LLC’s Form 13F-HR filing with the SEC under CIK 1615982.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$1.1B8,493,321 sh - —
Quality
$394.8M4,148,428 sh - —
Quality
$327.8M17,891,812 sh - —
Quality
$265.0M2,985,448 sh - 22.6
Quality
$115.0M1,180,000 sh - 8.4
Quality
$101.6M10,346,926 sh - —
Quality
$93.7M3,603,595 sh - —
Quality
$90.8M14,745,943 sh - —
Quality
$71.6M3,220,364 sh - —
Quality
$63.6M1,642,166 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Apogee Therapeutics, Inc.$APGE | — | $1.1B | 8,493,321 |
 Oruka Therapeutics, Inc.$ORKA | — | $394.8M | 4,148,428 |
 Erasca, Inc.$ERAS | — | $327.8M | 17,891,812 |
 Spyre Therapeutics, Inc.$SYRE | — | $265.0M | 2,985,448 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 22.6 | $115.0M | 1,180,000 |
 OCULAR THERAPEUTIX, INC$OCUL | 8.4 | $101.6M | 10,346,926 |
 Damora Therapeutics, Inc.$DMRA | — | $93.7M | 3,603,595 |
 Savara Inc$SVRA | — | $90.8M | 14,745,943 |
 Jade Biosciences, Inc.$JBIO | — | $71.6M | 3,220,364 |
 Cogent Biosciences, Inc.$COGT | — | $63.6M | 1,642,166 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Venrock Adviser, LLC's 33 positions.
Showing top 10 of 33 holdings.
Sector Allocation
Healthcare
$3.3B
Financials
$3.2M
Full Holdings — Venrock Adviser, LLC (Q2 2026)
All 33 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $APGE | Apogee Therapeutics, Inc. | $1.1B | 34.2% | +0% | — |
| 2 | $ORKA | Oruka Therapeutics, Inc. | $394.8M | 12.0% | +0% | — |
| 3 | $ERAS | Erasca, Inc. | $327.8M | 9.9% | +9% | — |
| 4 | $SYRE | Spyre Therapeutics, Inc. | $265.0M | 8.0% | -19% | — |
| 5 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $115.0M | 3.5% | +0% | 22.6 |
| 6 | $OCUL | OCULAR THERAPEUTIX, INC | $101.6M | 3.1% | +0% | 8.4 |
| 7 | $DMRA | Damora Therapeutics, Inc. | $93.7M | 2.8% | +0% | — |
| 8 | $SVRA | Savara Inc | $90.8M | 2.8% | +7% | — |
| 9 | $JBIO | Jade Biosciences, Inc. | $71.6M | 2.2% | +0% | — |
| 10 | $COGT | Cogent Biosciences, Inc. | $63.6M | 1.9% | -18% | — |
| 11 |  $VRDN | Viridian Therapeutics, Inc.\DE | $59.8M | 1.8% | -16% | 27.2 |
| 12 |  $VOR | Vor Biopharma Inc. | $56.0M | 1.7% | +0% | — |
| 13 |  $DYN | Dyne Therapeutics, Inc. | $48.3M | 1.5% | +0% | — |
| 14 |  $MAZE | Maze Therapeutics, Inc. | $47.8M | 1.4% | +0% | 10.3 |
| 15 |  $RLMD | RELMADA THERAPEUTICS, INC. | $47.4M | 1.4% | +41% | — |
| 16 |  $ORIC | Oric Pharmaceuticals, Inc. | $46.8M | 1.4% | +0% | — |
| 17 |  $CBIO | CRESCENT BIOPHARMA, INC. | $38.4M | 1.2% | +0% | 9.6 |
| 18 |  $ZURA | Zura Bio Ltd | $38.0M | 1.1% | +0% | — |
| 19 |  $ANL | Adlai Nortye Group Ltd. | $36.9M | 1.1% | +0% | — |
| 20 |  $ELVN | Enliven Therapeutics, Inc. | $26.7M | 0.8% | -70% | — |
| 21 |  $HELP | CYBIN INC. | $25.5M | 0.8% | +0% | — |
| 22 |  $CGEM | Cullinan Therapeutics, Inc. | $25.1M | 0.8% | +0% | — |
| 23 |  $IPSC | Century Therapeutics, Inc. | $21.3M | 0.7% | +0% | 33.5 |
| 24 |  $ARTV | Artiva Biotherapeutics, Inc. | $19.8M | 0.6% | +27% | 9.7 |
| 25 |  $CTMX | CytomX Therapeutics, Inc. | $18.7M | 0.6% | -50% | 8.7 |
| 26 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $18.0M | 0.5% | NEW | — |
| 27 |  $PBLS | Parabilis Medicines, Inc. | $17.1M | 0.5% | NEW | — |
| 28 |  $SRZN | Surrozen, Inc./DE | $16.4M | 0.5% | +0% | — |
| 29 |  $KRRO | Korro Bio, Inc. | $13.3M | 0.4% | +0% | 14.1 |
| 30 |  $ANRO | Alto Neuroscience, Inc. | $13.2M | 0.4% | +0% | — |
| 31 |  $XFOR | X4 Pharmaceuticals, Inc | $9.0M | 0.3% | +485% | 28 |
| 32 |  $RACC | Research Alliance Corp III | $3.2M | 0.1% | NEW | — |
| 33 |  $INM | InMed Pharmaceuticals Inc. | $50,662 | 0.0% | NEW | 13.1 |
New Positions (4)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Venrock Adviser, LLC including:
Track Venrock Adviser, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Venrock Adviser, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Venrock Adviser, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Venrock Adviser, LLC (SEC CIK: 1615982), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Venrock Adviser, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.